Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 0.57 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1264476 | 0.88 | HDAC6 (0.52) | ABCB1ABCC1KMT2ANPC1HDAC6 | |
| SCHEMBL1264116 | 0.84 | HDAC6 (0.49) | ABCB1ABCC1KMT2ANPC1SMPD1 | |
| SCHEMBL1264149 | 0.82 | HDAC6 (0.68) | ABCB1ABCC1KMT2ANPC1HDAC6 | |
| SCHEMBL5096699 | 0.80 | KMT2A (0.86) | ABCB1ABCC1KMT2ANPC1MEN1 | |
| SCHEMBL1264115 | 0.75 | HDAC6 (0.60) | KMT2ANPC1HDAC6HDAC1HDAC8 | |
| SCHEMBL1263101 | 0.73 | HDAC6 (0.49) | KMT2AHDAC6HDAC1HDAC8MEN1 | |
| SCHEMBL1264391 | 0.73 | KMT2A (0.54) | ABCB1ABCC1KMT2ANPC1HDAC6 | |
| SCHEMBL5446338 | 0.72 | KMT2A (0.52) | ABCB1ABCC1KMT2ANPC1MEN1 | |
| SCHEMBL17702005 | 0.71 | HDAC6 (0.47) | KMT2AHDAC6HDAC1HDAC8HDAC10 | |
| SCHEMBL1264363 | 0.71 | PKM (0.57) | KMT2AHDAC6MEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096518-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-08-04 | — | — | US | claimed |
| US-9321731-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-9321731-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-9321731-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20160031820-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160031820-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160031820-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-9096518-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096518-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096518-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20110039827-A1 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039827-A1 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039827-A1 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| WO-2010151318-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039827-A1 | Substituted hydroxamic acids and uses thereof | HDAC6, HDAC5, HDAC1 | ABCB1 3073/4885ABCC1 2987/4885KMT2A 37/4885 |
| US-20160031820-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC5, HDAC1 | ABCB1 3073/4885ABCC1 2987/4885KMT2A 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.